# US 9,895,439 B2 · Combined treatment with netrin-1 interfering drug and chemotherapeutic drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,895,439 B2
- Document ID: US9895439B2
- Status: Granted
- Kind: B2
- Application number: 14/427,426
- Filed: 2013-09-12
- Published: 2015-09-03
- Granted: 2018-02-20
- Earliest claimed: 2012-09-12
- Assignees: Netris Pharma
- Applicants: Netris Pharma
- Inventors: Patrick Mehlen; Andréa Paradisi; Pascale Nony
- Web page: https://patentgrep.com/patent/US9895439B2

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo, in a pharmaceutically acceptable carrier or vehicle. The chemotherapeutic drug is selected from those able to induce over expression of netrin-1 in cancer cells. The combination is associated with synergic anti-cancer effect.

## Claims

### Claim 1

A method for treating cancer cells expressing or overexpressing netrin-1 and expressing a netrin-1 receptor, comprising administering an effective amount of a chemotherapeutic drug and of a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo to a patient having cancer cells expressing or over-expressing netrin-1 and expressing a netrin-1 receptor, wherein the chemotherapeutic drug is able to induce an expression or over-expression of netrin-1 in the treated cancer cells, and the netrin-1 interfering drug is an antibody specifically binding to netrin-1 which upon binding to netrin-1 specifically inhibits the binding of netrin-1 to its receptor on the treated cancer cells and promotes netrin-1 receptors-induced apoptosis of the treated cancer cells expressing a netrin-1 receptor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the netrin-1 interfering drug promotes netrin-1 receptors-induced apoptosis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the chemotherapeutic drug is selected from the group consisting of doxorubicin, 5-fluorouracil (5FU), paclitaxel and cisplatin.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the chemotherapeutic drug and the netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo, are administered simultaneously, separately, or sequentially to said patient.